NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 85 resultados LastUpdate Última actualización 30/09/2022 [08:46:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


Bispecific Anti-BCMA x Anti-CD3 Antibodies and Uses Thereof

NºPublicación: US2022306758A1 29/09/2022

Solicitante:

REGENERON PHARMA [US]

JP_2021531005_A

Resumen de: US2022306758A1

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.

traducir

INHIBITORS OF ADRENOMEDULLIN FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA BY ERADICATING LEUKEMIC STEM CELLS

NºPublicación: EP4061944A1 28/09/2022

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV TOULOUSE 3 PAUL SABATIER [FR]

WO_2021099600_A1

Resumen de: WO2021099600A1

The emergence of cells with drug resistant and/or stem cell features might explain frequent relapses and the poor outcome of patients with acute myeloid leukemia (AML). LSCs are heterogeneous for their phenotypes and their sensitivity to chemotherapeutic agents in vivo. Using in silico and functional approaches, the inventors uncovered that CALCRL is overexpressed in LSCs compared with normal hematopoietic cells. They further demonstrated that the CALCRL ligand adrenomedullin (ADM) is highly expressed in AML cells and that increased transcript level was markedly associated with decreased complete remission rates, 5-year overall and event7free survival. The inventors also showed that CALCRL depletion strongly affected leukemic growth in vivo and increased mice survival. Targeting ADM phenocopies the biological and anti-leukemic effects of the CALCRL depletion. These data highlight the critical role of ADM and disclose a promising therapeutic target to specifically eradicate R-LSCs and overcome relapse in AML.

traducir

METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

NºPublicación: EP4061967A1 28/09/2022

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV COTE D'AZUR [FR]
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
UNIV COLUMBIA [US]

WO_2021099573_A1

Resumen de: WO2021099573A1

In the present invention, inventors have used high throughput sequencing to identify novel mutations in ABCA1 in CMML patient samples. Further studies in a mouse model of myelomonocytic leukemia driven by hematopoietic Tet2 deficiency have shown that these somatic mutations abrogate the tumor suppressor function of WT ABCA1, resulting in the failure to suppress canonical IL3-receptor beta signaling-driven myelopoiesis. The loss of the myelo-suppressive function of ABCA1 mutants can be overcome by raising HDL levels through overexpression of the human apolipoprotein A-1 (apoA-1) transgene. Inventors have also shown that both IL-3Rbeta blocking antibody and cyclodextrin prevented the proliferation of ABCA1 mutant-transduced Tet2 deficient BM cells similar to the effect of ABCA1-WT overexpression. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from CMML comprising the step identifying at least one ABCA1 and to a method for treating said subject with HDL/ABCA recombinant (ApoA-1); cylodextrin and/or anti-IL-3Rbeta antibody.

traducir

COMBINATION THERAPY WITH AN ANTI-CD19 ANTIBODY AND A NITROGEN MUSTARD

NºPublicación: EP4062936A1 28/09/2022

Solicitante:

MORPHOSYS AG [DE]

ES_2909722_T3

Resumen de: EP4062936A1

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

traducir

METHOD FOR DETECTING CANCER BONE METASTASIS AND DETECTION REAGENT

NºPublicación: EP4063845A1 28/09/2022

Solicitante:

UNIV OSAKA [JP]
TOSOH CORP [JP]

CN_114729947_PA

Resumen de: EP4063845A1

A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.

traducir

CARBONIC ANHYDRASE 1 (CA1) INHIBITORS FOR THE TREATMENT OR PREVENTION OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES, AND AS BIOMARKER OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES

NºPublicación: EP4062909A1 28/09/2022

Solicitante:

COMMISSARIAT ENERGIE ATOMIQUE [FR]
INST NAT SANTE RECH MED [FR]
UNIV PARIS [FR]
UNIV PARIS SACLAY [FR]

Resumen de: EP4062909A1

The invention relates to the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies.Herein is described a carbonic Anhydrase 1 (CA1) inhibitor; for use in a method for treating or preventing a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis.Herein is further described the use of carbonic Anhydrase 1 as a biomarker for myeloproliferative disorders and other hematopoietic malignancies; and/or as a biomarker of the efficacy of compounds for treating or preventing said conditions.

traducir

COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS

NºPublicación: WO2022197933A1 22/09/2022

Solicitante:

BROAD INST INC [US]
DANA FARBER CANCER INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]

Resumen de: WO2022197933A1

The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.

traducir

HLA-DR-SPECIFIC GAMMA DELTA TCR CONSTRUCTS AND USE THEREOF

NºPublicación: WO2022195073A1 22/09/2022

Solicitante:

MEDIZINISCHE HOCHSCHULE HANNOVER [DE]

EP_4059955_PA

Resumen de: WO2022195073A1

The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and y8 (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.

traducir

B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES

NºPublicación: WO2022194988A2 22/09/2022

Solicitante:

HEIDELBERG PHARMA RES GMBH [DE]

Resumen de: WO2022194988A2

The present application relates to conjugates comprising an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.

traducir

THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS FOR TREATING CUTANEOUS LYMPHOMA

NºPublicación: WO2022195118A1 22/09/2022

Solicitante:

ELIGO BIOSCIENCE [FR]

US_2022296686_PA

Resumen de: WO2022195118A1

The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use in the treatment of cutaneous T-cell lymphoma (CTCL) in a subject, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the treatment of CTCL in said subject.

traducir

PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

NºPublicación: WO2022197930A2 22/09/2022

Solicitante:

BROAD INST INC [US]
DANA FARBER CANCER INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]

Resumen de: WO2022197930A2

The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.

traducir

ANTI-BAFFR ANTIBODY AND APPLICATION THEREOF

NºPublicación: WO2022194067A1 22/09/2022

Solicitante:

SHENGHE CHINA BIOPHARMACEUTICAL CO [CN]

CN_115073598_PA

Resumen de: WO2022194067A1

Disclosed in the present invention are an anti-BAFFR antibody or an antigen-binding fragment thereof, a use thereof, and a pharmaceutical composition. The anti-BAFFR antibody provided by the present invention can specifically bind to BAFFR, block the BAFFR-BAFF signaling pathway, clear hyperproliferative B lymphocytes, and inhibit the growth of the B cells. The problem of drug resistance of existing drugs for treating B cell lymphoma is effectively solved.

traducir

PERIPHERAL BLOOD TCR MARKER FOR ACUTE MYELOID LEUKAEMIA, AND TEST KIT AND APPLICATION THEREOF

NºPublicación: WO2022194042A1 22/09/2022

Solicitante:

CHENGDU EXAB BIOTECHNOLOGY CO LTD [CN]

CN_113109564_A

Resumen de: WO2022194042A1

A peripheral blood TCR marker for acute myeloid leukaemia, and a test kit and an application thereof, the marker comprising at least one of the proteins of the sequences shown in SEQ ID NO. 1-100. The present invention is based on a high throughput sequencing method, and only a small amount of peripheral blood needs to be taken; RNA is extracted, an immunoassay library is established by means of processing the samples, and high throughput sequencing and TCR data analysis are performed, first determining characteristic TCR sequences in acute myeloid leukaemia peripheral blood, and then comparing the test result of a sample to be tested with the characteristic TCR sequences to determine whether there is acute myeloid leukaemia; the present invention can simultaneously compare a large number of acute myeloid leukaemia-specific TCR sequences, having higher specificity and accuracy compared to individual detection of one or several markers, and thereby improving diagnosis efficiency.

traducir

PERIPHERAL BLOOD TCR MARKER FOR ACUTE B LYMPHOCYTIC LEUKEMIA, AND DETECTION KIT THEREOF AND USE THEREOF

NºPublicación: WO2022194039A1 22/09/2022

Solicitante:

CHENGDU EXAB BIOTECHNOLOGY CO LTD [CN]

CN_113030473_A

Resumen de: WO2022194039A1

A peripheral blood TCR marker for acute B lymphocytic leukemia, and a detection kit thereof and the use thereof. The peripheral blood TCR marker for acute B lymphocytic leukemia comprises at least one of proteins having sequences as shown in SEQ ID NOs.1-100. The method is based on a high-throughput sequencing method, and comprises: only collecting a small amount of peripheral blood, extracting RNA, establishing an immune spectrum library by means of treating a sample, then performing high-throughput sequencing and TCR data analysis to firstly determine the characteristic TCR sequence in the peripheral blood from a subject with acute B lymphocytic leukemia, and then comparing the detection result of a sample to be subjected to detection with the characteristic TCR sequence, thereby determining whether the subject suffers from acute B lymphocytic leukemia. The method can be used to simultaneously compare a large number of the specific TCR sequences of acute B lymphocytic leukemia, has a higher specificity and accuracy compared with the detection of one or several markers alone, thereby improving the efficiency of diagnosis.

traducir

PERIPHERAL BLOOD TCR MARKER FOR CLASSICAL HODGKIN LYMPHOMA, DETECTION KIT THEREFOR, AND APPLICATION THEREOF

NºPublicación: WO2022194036A1 22/09/2022

Solicitante:

CHENGDU EXAB BIOTECHNOLOGY CO LTD [CN]

CN_113125724_A

Resumen de: WO2022194036A1

A peripheral blood TCR marker for classical Hodgkin lymphoma, a detection kit therefor, and an application thereof. The marker comprises at least one of proteins of which sequences are as shown in SEQ ID NOs. 1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be used, RNA is extracted, and an immune map library is established by treating a sample; then by means of high-throughput sequencing and TCR data analysis, a characteristic TCR sequence in the peripheral blood of classical Hodgkin lymphoma is determined first, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, so as to determine whether a patient suffers from classical Hodgkin lymphoma. A huge number of specific TCR sequences of classical Hodgkin lymphoma can be compared at the same time, and compared with separate detection of one or more markers, the present invention has higher specificity and accuracy, and improves diagnosis efficiency.

traducir

PERIPHERAL BLOOD TCR MARKER FOR DIFFUSE LARGE B-CELL LYMPHOMA, AND DETECTION KIT AND USE THEREFOR

NºPublicación: WO2022194033A1 22/09/2022

Solicitante:

CHENGDU EXAB BIOTECHNOLOGY CO LTD [CN]

CN_113092761_A

Resumen de: WO2022194033A1

A peripheral blood TCR marker for diffuse large B-cell lymphoma, and a detection kit and use therefor. The marker comprises at least one among proteins having sequences shown in SEQ ID NO. 1-100. According to the high-throughput sequencing method: only requiring a small amount of peripheral blood, extracting RNA is extracted, establishing an immune map library by means of processing samples, then carrying out high-throughput sequencing and TCR data analysis, first determining a characteristic TCR sequence in the peripheral blood of the diffuse large B-cell lymphoma, and then comparing a test result of a sample to be tested with the characteristic TCR sequence, so as to determine whether diffuse large B cell lymphoma exists. The present solution compares a large number of diffuse large B cell lymphoma specific TCR sequences at the same time, and compared with separately detecting one or more markers, has higher specificity and accuracy, and improves diagnosis efficiency.

traducir

NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE

NºPublicación: WO2022197690A1 22/09/2022

Solicitante:

UNIV MICHIGAN REGENTS [US]

Resumen de: WO2022197690A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).

traducir

METHODS AND MATERIALS FOR IDENTIFYING MYELOMA STAGE AND DRUG SENSITIVITY AND TREATING MYELOMA

NºPublicación: WO2022197934A1 22/09/2022

Solicitante:

MAYO FOUND MEDICAL EDUCATION & RES [US]

Resumen de: WO2022197934A1

Methods and materials for identifying and treating mammals (e.g., humans) having multiple myeloma (MM) are provided herein. For example, this document provides methods and materials that can be used to identify and treat mammals having advanced stage MM, and/or having MM that is resistant to treatment with immunomodulatory drugs (IMiDs) and/or proteasome inhibitors (PIs).

traducir

COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES

NºPublicación: US2022298251A1 22/09/2022

Solicitante:

NOVARTIS AG [CH]

US_2019135931_A1

Resumen de: US2022298251A1

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

traducir

DETECTION OF RELB ACTIVATION FOR PREDICTING A PROGNOSTIC IN B-CELL LYMPHOMA

NºPublicación: US2022298578A1 22/09/2022

Solicitante:

UNIV PARIS [FR]
INST NAT SANTE RECH MED [FR]

WO_2020260453_A1

Resumen de: US2022298578A1

The invention relates to a method for predicting the prognosis of a patient suffering from a B-cell lymphoma, through the detection of the status of activation of the RelB protein, in a biological sample of said patient. The inventors indeed identified an associated gene expression signature in the biological sample. Some genes from said signature are over-expressed and other are under-expressed and allow detecting RelB activation and predicting a worse prognosis in B-cell lymphoma.

traducir

ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT

NºPublicación: US2022298243A1 22/09/2022

Solicitante:

SQUIBB BRISTOL MYERS CO [US]
SEATTLE GENETICS INC [US]

US_2019218293_A1

Resumen de: US2022298243A1

This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

traducir

TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA

NºPublicación: US2022296607A1 22/09/2022

Solicitante:

LILLY CO ELI [US]

Resumen de: US2022296607A1

A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.

traducir

DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS

NºPublicación: WO2022197776A1 22/09/2022

Solicitante:

MAGENTA THERAPEUTICS INC [US]

Resumen de: WO2022197776A1

The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, such as a donor with multiple myeloma, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a patient with multiple myeloma for performing an autologous stem cell transplant to treat the patient's multiple myeloma.

traducir

PROMOTER HAVING HIGH ACTIVITY IN ACTIVATED T-CELL

NºPublicación: EP4060042A1 21/09/2022

Solicitante:

SHANGHAI CELL THERAPY GROUP CO LTD [CN]

WO_2021093831_A1

Resumen de: EP4060042A1

Provided is a promoter having high activity in an activated T-cell. The promoter comprises, from 5'-end to 3'-end, a CMV enhancer, an IFNγ promoter, and a long terminal repeat sequence from human T-cell leukemia virus that are connected in sequence. The promoter exhibits greater activity in an activated immune cell than the existing promoters and is low in activity or inactive in other non-immune cells.

traducir

HLA-DR-SPECIFIC GAMMA DELTA TCR CONSTRUCTS AND USE THEREOF

Nº publicación: EP4059955A1 21/09/2022

Solicitante:

MEDIZINISCHE HOCHSCHULE HANNOVER [DE]

WO_2022195073_PA

Resumen de: EP4059955A1

The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and γδ (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.

traducir

Página1 de 4 nextPage por página

punteroimgVolver